studies

mBC - TNBC - L2 - PDL1 positive, immune chekpoint inhibitors vs. all, meta-analysis of study results

OutcomeTE95% CInkI2ROBPub. bias deaths (OS)detailed resultsKEYNOTE-119 (PDL1 CPS>1), 2019 0.86 [0.69; 1.07] KEYNOTE-119 (PDL1 CPS>10), 2019 0.78 [0.57; 1.06] 0.83[0.70; 0.99]KEYNOTE-119 (PDL1 CPS>1), 2019, KEYNOTE-119 (PDL1 CPS>10), 201920%599moderatenot evaluable progression or deaths (PFS)detailed resultsKEYNOTE-119 (PDL1 CPS>1), 2019 1.35 [1.08; 1.68] KEYNOTE-119 (PDL1 CPS>10), 2019 1.14 [0.82; 1.59] 1.28[1.07; 1.54]KEYNOTE-119 (PDL1 CPS>1), 2019, KEYNOTE-119 (PDL1 CPS>10), 201920%599moderatenot evaluable objective responses (ORR)detailed resultsKEYNOTE-119 (PDL1 CPS>1), 2019 1.35 [0.72; 2.54] KEYNOTE-119 (PDL1 CPS>10), 2019 2.13 [0.90; 5.04] 1.58[0.95; 2.64]KEYNOTE-119 (PDL1 CPS>1), 2019, KEYNOTE-119 (PDL1 CPS>10), 201920%599moderatenot evaluable0.55.01.0relative treatment effectwww.metaEvidence.org2024-11-01 00:40 +01:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 240 - treatments: 204,504,850,329,558,579,549,868,502,741,556,812,813,367,851,361,602,1070,671,865,744,696,1083,1281,1282,1283,1082,866,852,417,603,1051,876,853,1018,661,673,1049,1440,1561,854,374,953,672,1080,1560,1073,862,1562,1565,855,360,719,721,720,842,642,674,1085,863,503,847,982,359,575,577,576,869,1081,981,875,505,952,1021,1079,767,1071,1074,873,561,644,1251,1044,724,874,1043,1041,1042,940,1258,1563,746,745,856,634,861,416,864,769,980,369,743